Acute dystonic reaction to metoclopramide in patients carrying homozygous cytochrome P450 2D6 genetic polymorphisms by Padt, A. van der et al.
m a y  2 0 0 6 ,  V o l .  6 4 ,  N o .  5
C A s E  r E P o r T
Acute dystonic reaction to metoclopramide 
in patients carrying homozygous cytochrome 
P450 2d6 genetic polymorphisms
A. van der Padt1,2*, R.H.N. van Schaik3, P. Sonneveld2 
1Department of Internal Medicine, Ikazia Hospital, Rotterdam, the Netherlands, Departments 
of 2Haematology and 3Clinical Chemistry, Erasmus Medical Centre, Rotterdam, the Netherlands, 
*corresponding author: tel.: +31 (0)10-297 50 00, fax: +31 (0)10-485 99 59,  
e-mail: annemiekevanderpadt@yahoo.com
A B s T r A C T
Background: Extrapyramidal syndromes (EPs) are clinically 
relevant side effects of metoclopramide which are often not 
anticipated. 
Patients and methods: Two patients who received 
metoclopramide developed an acute dystonic reaction. 
symptoms disappeared after biperiden or trihexyphenidyl 
were given. Molecular analysis of the CYP2d6 gene was 
performed using a PCr-based method.
results: Both patients were homozygous for inactive 
CYP2d6 alleles (CYP2d6*4/*4 and CYP2d6*4/*5), which 
are associated with slow drug metabolism. 
Conclusion: Metoclopramide-induced acute dystonic 
reactions may occur in patients carrying a CYP2d6 genetic 
polymorphism. 
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i N T r o d u C T i o N
Metoclopramide is a selective dopamine antagonist 
(D2-R) with central and peripheral antidopaminergic 
effects. Metoclopramide increases peristaltic movements 
of the gut, it induces pyloric relaxation and has a direct 
antiemetic effect.1-3 Extrapyramidal syndromes (EPS) 
are clinically relevant side effects of metoclopramide, 
which are often not anticipated. We report two cases 
of an acute dystonic reaction to metoclopramide in 
two patients treated with chemotherapy who were 
homozygous carriers of CYP2D6 variant alleles, making 
them CYP2D6 poor metabolisers.
C A s E  r E P o r T s
Patient A, a 25-year-old female, was diagnosed with acute 
myeloid leukaemia (AML), French-American-British (FAB) 
classification AML-M1. She was treated with cytosine 
arabinoside and idarubicin (chemotherapy). Granisetron 
(1 mg intravenously) was given as prophylactic antiemetic 
drug. Because of persisting granisetron-refractory nausea 
after four days, metoclopramide 10 mg was prescribed 
intravenously four times daily. After two days, the patient 
felt cramps in her mouth and right hand, twisting of her 
neck to the right in combination with turning of her eyes 
to the right and above and she was unable to speak. After 
a short period of relaxation, her head and hand turned 
in the compulsion position again. She remained fully 
consciousness during this episode. 
An acute dystonic reaction was considered. The symptoms 
disappeared immediately upon administration of 5 mg 
biperiden (akineton) intravenously. No further dystonic 
reactions were noticed after stopping metoclopramide. 
Patient B, a 34-year-old male, was diagnosed with diffuse 
large B-cell non-Hodgkin lymphoma and was treated with 
CHOP chemotherapy (cyclophosphamide, doxorubicin, 
vincristine, prednisone). Metoclopramide tablets (10 mg) 
were prescribed for nausea. The next day the patient 
developed episodes of torticollis every five minutes. He 
had cramps in his neck and head to the left and backwards 
lasting for seconds to five minutes. During these episodes 
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he could not rotate his neck; he remained fully conscious. 
There were no signs of urinary incontinence, tongue bite 
injuries or tonic-clonic seizures. 
An acute dystonic reaction (torticollis) was diagnosed, due 
to metoclopramide. Trihexyphenidyl (artane) 1 mg was 
administered, upon which the symptoms disappeared. The 
symptoms did not recur after metoclopramide was stopped.
M E T h o d s
Genomic DNA was isolated from EDTA (Ethylene Diamine 
Tetra Acetic) blood. Detection of the *4 allele was performed 
using 5 ng of DNA in a polymerase chain reaction (PCR) 
with primers 5’-TCATGGCCACGCGCACGTGC-3’ and 
5’-ACTCCTCGGTCTCTCGCTCC-3’, for 35 cycles with 
conditions [1 min 94°C, 1 min 60°C, 1 min 72°C]. The 
460 bp PCR product was digested with BstN1 for two 
hours at 37°C. The *4 allele will give a specific 347 bp band. 
For the *5 allele, 20 ng of genomic DNA was amplified 
with primers 5’-ACCGGGCACCTGTACTCCTCA-3’ and 
5’-GCATGAGCTAAGGCACCCAGA-3’ in a 35 cycle PCR 
with conditions [1 min 94°C, 30 sec 65°C, 5 min 68°C]. 
The appearance of a 3.5 kb PCR product indicates the 
presence of a *5 allele.
r E s u l T s
Patient A was genotyped as CYP2D6*4/*5 and patient B 
was genotyped as CYP2D6*4/*4. Both the *4 and *5 alleles 
encode nonfunctional CYP2D6 enzyme, making both 
patients poor metabolisers of CYP2D6.
d i s C u s s i o N
Nausea can be induced in several ways. The vomiting 
centre receives signals from the gut, the vestibular 
labyrinths and the ‘chemoreceptor trigger zone (CRT)’, 
which is located in the area postrema of the medulla 
oblongata.4 The dopamine (type 2), serotonin (type 3), 
histamine (type 1) and muscarine receptors are located 
here. Emesis is induced when these receptors are activated 
by their respective neurotransmitters. Specific antagonists 
of these receptors are used to treat symptoms of nausea.5 
Metoclopramide is used for treatment of oesophageal 
reflux, dyspepsia, gastroparesis and for chemotherapy-
related nausea.1,2,6 Metoclopramide blocks the dopamine 
receptor (D2-R) both centrally as well as peripherally. It 
stimulates the acetylcholine receptors, which are located on 
the musculature of the stomach.7 When metoclopramide 
is prescribed at a high dose it has an antagonistic effect 
on the serotonin (5-HT3) receptors.8 This observation 
triggered the development of selective 5-HT3-antagonists.7,9 
The antagonistic effects of ondansetron are 100 times 
more potent than metoclopramide at the chemoreceptor 
trigger zone.10
EPS due to metoclopramide are observed in 1:500 
patients.6,11 Persons at risk are young women, patients 
with a family history of neurological disorders and those 
who are treated with neuroleptics.12
EPS which have been associated with metoclopramide 
include tardive dyskinesia, drug-induced parkinsonism, 
akathisia, malignant neuroleptic syndrome and an acute 
dystonic reaction.6,11
An acute dystonic reaction is defined as sustained 
muscular spasms producing twisting, squeezing and 
pulling movements.6 Specific clinical symptoms are 
torticollis, opisthotonus, blepharospasms and ocular crises. 
Respiratory and swallowing problems can lead to life-
threatening situations.6,13 Symptoms often start within 
24 hours after administration of a dopamine antagonist 
and 94% of these symptoms occur within 72 hours.14
Several studies indicate that these reactions especially 
occur in women aged between 12 and 19 years. They have 
three to four times more chance of developing these side 
effects.6,13,15 Acute dystonia is rarely observed in the elderly, 
due to loss of dopamine receptors.6
Metoclopramide is an inhibitor as well as a substrate of the 
hepatic cytochrome P450 enzyme, subclass CYP2D6. Drug-
induced EPS are more frequently observed in patients with 
a genetic polymorphism in the gene coding for CYP2D6, 
resulting in an absent enzyme activity.16,17 Molecular 
analysis of this gene was therefore performed using a PCR-
based method. Both patients were homozygous for inactive 
CYP2D6, alleles (CYP2D6*4/*4 and CYP2D6*4/*5), 
making them poor metabolisers. Of the Caucasian 
population, 5 to 10% are poor metabolisers of CYP2D6. 
However, the incidence of EPS due to metoclopramide is 
only 1:500 patients.17 It is hypothesised that simultaneous 
use of metoclopramide with drugs that are metabolised 
by CYP2D6 such as antidepressants and neuroleptics, 
may provoke EPS. The metabolism of metoclopramide 
may then be affected more seriously in patients who carry 
homozygous CYP2D6 nonfunctional alleles, leading to 
drug accumulation and related toxicities such as EPS.18 
Both patients were treated with chemotherapy, idarubicin 
and doxorubicin respectively, which are metabolised by 
CYP2D6. Therefore, they are more at risk for developing 
an acute dystonic reaction. 
Searching for nonfunctional CYP2D6 would be interesting 
if a patient is at risk for EPS and if there is no good 
alternative treatment for metoclopramide. However, there 
is not much written in the literature about the incidence 
of patients developing an acute dystonic reaction who are 
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known as poor metabolisers of CYP2D6. There is a rational 
relation considering our two patients. More research is 
necessary before it can be tested routinely.
There are several therapeutic options for acute dystonic 
reactions after administration of metoclopramide. First of 
all, metoclopramide should be stopped. Secondly, various 
therapeutic interventions can be considered. Dysbalance 
between agonists and antagonists of musculature is seen 
when a dopamine antagonist, such as metoclopramide, is 
administered. Through other neurotransmitters (gamma-
aminobutyric acid (GABA) and acetylcholine) an extra 
activation will take place and induce muscular spasms.19 
Blocking these neurotransmitters will inhibit the dystonic 
reaction. However, GABA derivates (for example baclofen) 
and dopamine agonists (for example bromocriptine) are 
only available for oral use, which will produce a delayed 
effect after 30 minutes.
Direct intravenous administration of anticholinergics (for 
example biperiden 5 mg or promethazine 25-50 mg) is the 
treatment of choice for acute dystonic reaction since they 
provide an immediate effect. Benzodiazepines (diazepam 2 
to 20 mg iv or im) induce immediate muscle relaxation and 
can be used in combination with anticholinergics.20 
Although both patients are poor metabolisers, they 
remained free of symptoms after one dose of biperiden 
and trihexyphenidyl, respectively. Normally the half-life 
of metoclopramide is four to six hours and for the other 
drugs 16 to 33 hours and 6 to 12 hours, respectively. The 
blood level of metoclopramide is probably reduced when 
biperiden or trihexyphenidyl are eliminated, so that the 
dystonia does not return. 
C o N C l u s i o N
Metoclopramide is an antiemetic drug which can cause a 
severe adverse event, such as an acute dystonic reaction, 
especially in patients carrying homozygous CYP2D6 
genetic polymorphisms. If a patient is at risk for an 
acute dystonic reaction and there is a good alternative, 
metoclopramide use should be avoided. The most rapid 
treatment of an acute dystonic reaction by metoclopramide 
is administration of anticholinergics or benzodiazepines 
intravenously or intramuscularly.
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